Brimonidine-d4

Brimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine (Cay-15426) by GC- or LC-MS. Brimonidine is an agonist of alpha2-adrenergic receptors (alpha2-ARs, Kis = 2.7, 52, and 44 nM for alpha2A, alpha2B, and alpha2C-ARs, respectively, in CHO cells). It is selective for alpha2-ARs over alpha1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution. It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day. Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.Formal Name: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d4)quinoxalin-6-amine. CAS Number: 1184971-51-4. Molecular Formula: C11H6BrD4N5. Formula Weight: 296.2. Purity: >99% deuterated forms (d1-d4). Formulation: (Request formulation change), A solid. Solubility: DMSO: soluble, Water: 1.5 mg/ml. SMILES: BrC1=C(NC2=NC([2H])([2H])C([2H])([2H])N2)C=CC3=C1N=CC=N3. InChi Code: InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)/i5D2,6D2. InChi Key: XYLJNLCSTIOKRM-NZLXMSDQSA-N.